BRPI0815327A2 - "compostos de piperidina do tipo quinoxalina substituída e os usos destes" - Google Patents
"compostos de piperidina do tipo quinoxalina substituída e os usos destes"Info
- Publication number
- BRPI0815327A2 BRPI0815327A2 BRPI0815327A BRPI0815327A BRPI0815327A2 BR PI0815327 A2 BRPI0815327 A2 BR PI0815327A2 BR PI0815327 A BRPI0815327 A BR PI0815327A BR PI0815327 A BRPI0815327 A BR PI0815327A BR PI0815327 A2 BRPI0815327 A2 BR PI0815327A2
- Authority
- BR
- Brazil
- Prior art keywords
- piperidine compounds
- type piperidine
- substituted quinoxaline
- quinoxaline
- substituted
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96699407P | 2007-08-31 | 2007-08-31 | |
US98979107P | 2007-11-21 | 2007-11-21 | |
US4636408P | 2008-04-18 | 2008-04-18 | |
US8246408P | 2008-07-21 | 2008-07-21 | |
PCT/IB2008/002291 WO2009027820A2 (en) | 2007-08-31 | 2008-08-29 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0815327A2 true BRPI0815327A2 (pt) | 2015-12-15 |
Family
ID=40260760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0815327A BRPI0815327A2 (pt) | 2007-08-31 | 2008-08-29 | "compostos de piperidina do tipo quinoxalina substituída e os usos destes" |
Country Status (20)
Country | Link |
---|---|
US (3) | US8846929B2 (pt) |
EP (6) | EP2433937B1 (pt) |
JP (2) | JP5554709B2 (pt) |
KR (3) | KR101527842B1 (pt) |
CN (1) | CN101878208B (pt) |
AU (1) | AU2008291823B2 (pt) |
BR (1) | BRPI0815327A2 (pt) |
CA (1) | CA2697051C (pt) |
CO (1) | CO6270361A2 (pt) |
DK (1) | DK3564240T3 (pt) |
ES (3) | ES2920605T3 (pt) |
HK (2) | HK1168843A1 (pt) |
IL (1) | IL203914A (pt) |
MX (1) | MX2010002449A (pt) |
MY (1) | MY150602A (pt) |
NZ (1) | NZ582940A (pt) |
PH (1) | PH12013500913A1 (pt) |
RU (2) | RU2488585C2 (pt) |
TW (2) | TWI448289B (pt) |
WO (1) | WO2009027820A2 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2433937B1 (en) * | 2007-08-31 | 2016-06-29 | Purdue Pharma LP | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
DK2247292T3 (en) * | 2008-03-05 | 2017-06-06 | Merck Patent Gmbh | PYRIDOPYRAZINO DERIVATIVES, AS INSULIN SECRETION STIMULATORS, PROCEDURES FOR OBTAINING THESE AND USE THEREOF IN THE TREATMENT OF DIABETES |
PT2324013E (pt) | 2008-07-21 | 2012-12-24 | Purdue Pharma Lp | Compostos de piperidina ligados por pontes do tipo de quinoxalina substituída e as respectivas utilizações |
EP2394997A4 (en) * | 2009-02-03 | 2012-07-18 | Mitsubishi Tanabe Pharma Corp | PROCESS FOR PREPARING 1- (4-PIPERIDINYL) BENZIMIDAZOLONE DERIVATIVES |
AU2011245987B2 (en) | 2010-04-28 | 2016-12-15 | Kyowa Hakko Kirin Co., Ltd | Cationic lipid |
WO2011136369A1 (ja) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | カチオン性脂質 |
WO2012078633A2 (en) | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
JP5872585B2 (ja) * | 2010-12-22 | 2016-03-01 | パーデュー、ファーマ、リミテッド、パートナーシップ | リン置換キノキサリンタイプピペリジン化合物とその使用 |
JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
EP2776444A4 (en) | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
EP2797912B1 (en) | 2011-12-01 | 2016-05-25 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof |
US9085561B2 (en) | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
WO2014102594A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
US9040533B2 (en) * | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
WO2014102589A1 (en) * | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Quinazolin-4(3h)-one-type piperidine compounds and uses thereof |
WO2014102590A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
WO2014102588A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Indole and indoline-type piperidine compounds and uses thereof |
TN2016000203A1 (en) | 2013-12-20 | 2017-10-06 | Esteve Labor Dr | Piperazine derivatives having multimodal activity against pain. |
US10407547B2 (en) | 2014-05-12 | 2019-09-10 | Micromidas, Inc. | Methods of producing compounds from 5-(halomethyl)furfural |
JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
CN107973755B (zh) * | 2018-01-08 | 2020-12-29 | 滨州学院 | 一种3-乙酰氨基喹喔啉酮衍生物的制备方法 |
KR20230149877A (ko) | 2018-01-24 | 2023-10-27 | 퍼듀 퍼머 엘피 | 수면 장애 치료 및 예방 |
UA126880C2 (uk) * | 2019-01-31 | 2023-02-15 | Пурдуе Фарма Л.П. | Поліморфна форма сполуки заміщеного хіноксаліну-піперидину місткового типу |
US20240067645A1 (en) * | 2020-11-26 | 2024-02-29 | Lg Chem, Ltd. | Heterocyclic compound as diacylglycerol kinase inhibitor and use thereof |
RU2755123C1 (ru) * | 2020-11-26 | 2021-09-13 | федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" | Способ получения (6R,8R,10S,12R,13aR)-5-метил-3,6,7,8,9,10,11,12,13,13а-декагидро-1Н-2,6:6а,10:8,12-триметаноциклонона[c]-азоцина |
WO2023250190A1 (en) * | 2022-06-24 | 2023-12-28 | Purdue Pharma L.P. | Methods of treating or preventing overactive bladder syndrome |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS5811871B2 (ja) * | 1975-05-23 | 1983-03-04 | 第一製薬株式会社 | ピペリジルベンズイミダゾ−ルユウドウタイノセイゾウホウ |
US3963727A (en) * | 1975-06-06 | 1976-06-15 | Daiichi Seiyaku Co., Ltd. | 1,2 Disubstituted benzimidazole derivatives |
JPS5811873B2 (ja) * | 1975-06-11 | 1983-03-04 | 第一製薬株式会社 | ピペリジルベンゾイミダゾ−ルユウドウタイノセイゾウホウ |
JPS5823397B2 (ja) * | 1975-06-12 | 1983-05-14 | 第一製薬株式会社 | ピペリジルペンゾイミダゾ−ルユウドウタイノ セイホウ |
NZ181256A (en) | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP2550456B2 (ja) * | 1990-11-06 | 1996-11-06 | 山之内製薬株式会社 | 縮合ピラジン誘導体 |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
AU691829B2 (en) * | 1993-07-16 | 1998-05-28 | Merck & Co., Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
GB9314977D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Spa | Chemical compounds |
US5739129A (en) * | 1994-04-14 | 1998-04-14 | Glaxo Wellcome Inc. | CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines |
PE27497A1 (es) * | 1994-04-15 | 1997-08-07 | Glaxo Inc | Derivados de 1,5 benzodiazepina |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
BR9510360A (pt) * | 1994-12-23 | 1997-12-23 | Thomae Gmbh Dr K | Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação |
CA2224517A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
CA2291094C (en) * | 1997-05-30 | 2008-02-26 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivative |
WO1999032481A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
ES2175925T3 (es) * | 1998-01-19 | 2002-11-16 | Pfizer | Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. |
SE9800836D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
EP1067123B1 (en) | 1998-03-31 | 2011-01-19 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenous heterocyclic compounds |
CA2319554C (en) | 1998-03-31 | 2005-06-28 | Warner-Lambert Company | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
MA26659A1 (fr) * | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
CA2347938A1 (en) * | 1998-10-20 | 2000-04-27 | Takahiro Matsumoto | 1,5-benzodiazepine compounds, their production and use |
EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
AU1569501A (en) | 1999-11-09 | 2001-06-06 | Eli Lilly And Company | Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis |
ATE302770T1 (de) * | 1999-12-06 | 2005-09-15 | Euro Celtique Sa | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben |
DE60023100T2 (de) * | 2000-01-05 | 2006-07-06 | Pfizer Inc. | Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten |
GB0005642D0 (en) * | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
AU6594401A (en) | 2000-05-24 | 2001-12-03 | Bayer Aktiengesellschaft | 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines |
GB0017690D0 (en) | 2000-07-20 | 2000-09-06 | Weatherford Lamb | Improvements in valves |
US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
AU2002257114A1 (en) | 2001-04-06 | 2002-10-21 | Schering Corporation | Treatment of malaria with farsenyl protein transferase inhibitors |
YU82403A (sh) * | 2001-04-18 | 2006-08-17 | Euroceltique S.A. | Jedinjenja spiropirazola |
EP1997818A3 (en) * | 2001-04-18 | 2009-04-08 | Euro-Celtique S.A. | Quinolinone derivatives and their use to treat pain |
EP2050450A1 (en) * | 2001-04-18 | 2009-04-22 | Euro-Celtique S.A. | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain |
US6828440B2 (en) * | 2001-04-18 | 2004-12-07 | Euro-Celtique, S.A. | Spiroindene and spiroindane compounds |
DK1975164T3 (da) * | 2001-04-18 | 2010-05-25 | Euro Celtique Sa | Octahydrobenzimidazolon-forbindelser som analgetika |
PE20030320A1 (es) * | 2001-07-17 | 2003-04-03 | Gruenenthal Chemie | Derivados sustituidos de 4-aminociclohexanol |
US20030134846A1 (en) * | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
JPWO2003062234A1 (ja) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
US7026312B2 (en) * | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
DE10211770A1 (de) * | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO2003082333A1 (fr) * | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remede contre les troubles du sommeil |
US7001901B2 (en) * | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
US7067658B2 (en) * | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
DE10343098A1 (de) | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
AR045939A1 (es) * | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
AR045843A1 (es) * | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
WO2005060947A2 (en) * | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
CA2555219A1 (en) | 2004-02-03 | 2005-08-18 | R. Richard Goehring | Synthesis of cyanoimino-benzoimidazoles |
DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
MX2007003061A (es) * | 2004-09-15 | 2007-05-21 | Schering Plough Ltd | Procedimiento para la preparacion de 8-azabiciclo[3.2.1]octan-3- oles sustituidos. |
WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
EP1692939A1 (en) * | 2005-02-19 | 2006-08-23 | Bayer CropScience S.A. | Pesticidal substituted piperidines |
JP2008088057A (ja) * | 2005-03-23 | 2008-04-17 | Nippon Chemiphar Co Ltd | N−置換−n−(4−ピペリジニル)アミド誘導体 |
JP2006327947A (ja) | 2005-05-23 | 2006-12-07 | Banyu Pharmaceut Co Ltd | 4−(2−オキソ−2,3−ジヒドロ−1h−ベンズイミダゾール−1−イル)ピペリジン−3−カルボン酸誘導体の効率的不斉合成 |
US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
WO2007050381A2 (en) * | 2005-10-24 | 2007-05-03 | Janssen Pharmaceutica, N.V. | 3-piperidin-4-yl-indole orl-1 receptor modulators |
PE20071159A1 (es) * | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
CN101374519A (zh) * | 2005-12-22 | 2009-02-25 | 弗特克斯药品有限公司 | 毒蕈碱性受体调节剂 |
TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
CN101595100B (zh) * | 2007-01-16 | 2014-06-11 | 普渡制药公司 | 作为orl-1配体的杂环取代的哌啶 |
JP5313865B2 (ja) * | 2007-03-01 | 2013-10-09 | 田辺三菱製薬株式会社 | ベンゾイミダゾール化合物およびその医薬用途 |
US7799806B2 (en) * | 2007-04-04 | 2010-09-21 | Hoffmann-La Roche Inc. | Substituted n-benzyl piperidines as somatostatin receptor modulators |
EP2433937B1 (en) * | 2007-08-31 | 2016-06-29 | Purdue Pharma LP | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
PT2324013E (pt) * | 2008-07-21 | 2012-12-24 | Purdue Pharma Lp | Compostos de piperidina ligados por pontes do tipo de quinoxalina substituída e as respectivas utilizações |
WO2014102589A1 (en) * | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Quinazolin-4(3h)-one-type piperidine compounds and uses thereof |
US9040533B2 (en) * | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
-
2008
- 2008-08-29 EP EP11188205.6A patent/EP2433937B1/en active Active
- 2008-08-29 RU RU2010108388/04A patent/RU2488585C2/ru active
- 2008-08-29 TW TW097133373A patent/TWI448289B/zh active
- 2008-08-29 KR KR1020107007100A patent/KR101527842B1/ko active IP Right Grant
- 2008-08-29 EP EP08806986.9A patent/EP2086958B1/en active Active
- 2008-08-29 DK DK19160618.5T patent/DK3564240T3/da active
- 2008-08-29 JP JP2010522469A patent/JP5554709B2/ja active Active
- 2008-08-29 KR KR1020147030748A patent/KR20140139125A/ko not_active Application Discontinuation
- 2008-08-29 CN CN200880104528.6A patent/CN101878208B/zh active Active
- 2008-08-29 MX MX2010002449A patent/MX2010002449A/es unknown
- 2008-08-29 WO PCT/IB2008/002291 patent/WO2009027820A2/en active Application Filing
- 2008-08-29 EP EP11188189A patent/EP2433935A1/en not_active Withdrawn
- 2008-08-29 EP EP16176601.9A patent/EP3101018B1/en active Active
- 2008-08-29 NZ NZ582940A patent/NZ582940A/xx unknown
- 2008-08-29 KR KR1020127022679A patent/KR20120102172A/ko not_active Application Discontinuation
- 2008-08-29 TW TW102108038A patent/TW201322983A/zh unknown
- 2008-08-29 EP EP11188195A patent/EP2433936A1/en not_active Withdrawn
- 2008-08-29 AU AU2008291823A patent/AU2008291823B2/en active Active
- 2008-08-29 CA CA2697051A patent/CA2697051C/en active Active
- 2008-08-29 EP EP19160618.5A patent/EP3564240B1/en active Active
- 2008-08-29 BR BRPI0815327A patent/BRPI0815327A2/pt not_active Application Discontinuation
- 2008-08-29 MY MYPI20100343 patent/MY150602A/en unknown
- 2008-08-29 ES ES19160618T patent/ES2920605T3/es active Active
- 2008-08-29 ES ES11188205.6T patent/ES2593706T3/es active Active
- 2008-08-29 ES ES08806986.9T patent/ES2534546T3/es active Active
-
2009
- 2009-10-14 HK HK12109467.1A patent/HK1168843A1/zh unknown
- 2009-10-14 HK HK09109471.0A patent/HK1130489A1/xx unknown
-
2010
- 2010-02-11 IL IL203914A patent/IL203914A/en active IP Right Grant
- 2010-02-24 US US12/712,042 patent/US8846929B2/en active Active
- 2010-03-26 CO CO10035578A patent/CO6270361A2/es active IP Right Grant
-
2012
- 2012-12-17 RU RU2012154570/04A patent/RU2012154570A/ru not_active Application Discontinuation
-
2013
- 2013-05-07 PH PH12013500913A patent/PH12013500913A1/en unknown
- 2013-12-20 JP JP2013263803A patent/JP2014094947A/ja not_active Withdrawn
-
2014
- 2014-07-14 US US14/331,034 patent/US9278967B2/en active Active
-
2016
- 2016-02-11 US US15/041,998 patent/US9527840B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815327A2 (pt) | "compostos de piperidina do tipo quinoxalina substituída e os usos destes" | |
BRPI0813244A2 (pt) | Compostos e seus usos 708 | |
BRPI0810928A2 (pt) | "composição farmacêutica" | |
BRPI0818625A2 (pt) | Composições de cuidados pessoais que compreendem sulfatos de undecila | |
BRPI0809795A2 (pt) | "antagonistas do trpv1 e usos deste". | |
CY2014030I1 (el) | Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate | |
BRPI0913806A2 (pt) | "composição" | |
BRPI0817881A2 (pt) | Compostos orgânicos e seus usos | |
BRPI0811716A2 (pt) | "artigo absorvente" | |
BRPI0810929A2 (pt) | "método para proteger" | |
BRPI0911031A2 (pt) | compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes | |
DK2610258T3 (da) | Substituerede piperidindihydrothienopyrimidiner | |
BRPI0815301A2 (pt) | "coluna de perfuração de poço" | |
BRPI0813955A2 (pt) | composições terapêuticas e o uso das mesmas | |
BRPI0817666A2 (pt) | Composição com proteção uv | |
BRPI0819070A2 (pt) | "composição energética comestível" | |
BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
FR2925984B3 (fr) | Mecanisme de securite d'embase | |
NO20083139L (no) | Anvendelse av hyllebærekstrakt | |
ITMO20070138A1 (it) | "impianto di macinazione" | |
BRPI0810047A2 (pt) | Compostos e seus usos 707 | |
FR2913694B1 (fr) | Elements regulateurs d'expression | |
BRPI0819420A2 (pt) | "artigo absorvente" | |
BRPI0809817A2 (pt) | "escova de dentes" | |
ES2619647T8 (es) | Compuestos de hapteno y composiciones y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: PURDUE PHARMA L .P (US) |